Targeted IL-2 therapy to reduce inhibitor antibodies in hemophilia
Immunocytokine therapy for immune modulation in hemophilia
This project uses a new IL-2–based immunocytokine (F5111) to boost regulatory immune cells and lower antibodies that block clotting factor treatment in people with hemophilia.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Indiana University Indianapolis NIH-funded |
| Lab location | 1 site (Indianapolis, United States) |
| Project ID | NIH-11252575 on NIH RePORTER |
What this research studies
This project will develop and characterize an IL-2–based immunocytokine (called F5111) designed to preferentially expand regulatory T cells that promote tolerance to clotting factor therapy. Researchers will study the drug's dosing, safety, duration in the body, and mechanism using laboratory and animal models of hemophilia, including models that mimic inhibitor formation and anaphylactic reactions. The goal of these preclinical studies is to show the approach lowers inhibitor formation and has fewer off-target immune effects so it can move toward human testing.
Who could benefit from this research
Good fit: Ideal future trial candidates would be people with hemophilia A or B who have developed inhibitors to replacement clotting factors or who are at high risk of developing inhibitors.
Not a fit: People without immune-mediated inhibitor problems, or whose bleeding is controlled without factor replacement, are unlikely to benefit from this immune‑modulation approach.
Why it matters
Potential benefit: If successful, this approach could prevent or reduce inhibitor antibodies that make clotting factor therapy ineffective, lowering bleeding risk and treatment burden for people with hemophilia.
How similar studies have performed: Low‑dose IL‑2 has expanded regulatory T cells in other immune diseases, but IL‑2–based immunocytokines like F5111 are a newer, less-tested approach in hemophilia.
Where this research is happening
Indianapolis, United States
- Indiana University Indianapolis — Indianapolis, United States (Active)
Researchers
- Principal investigator: Biswas, Moanaro — Indiana University Indianapolis
- Study coordinator: Biswas, Moanaro
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.